Rosuvastatin

Catalog No.

B1123

Competitive inhibitor of HMG-CoA reductase

Grouped product items
Size	Price	Stock	Qty
50mg	$116.00	In stock
100mg	$147.00	In stock

For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Background

Rosuvastatin is a competitive inhibitor of HMG-CoA reductase with IC50 of 11 nM.

Physical Appearance	A solid
Storage	Store at -20°C
M.Wt	481.54
Cas No.	287714-41-4
Formula	C22H28FN3O6S
Solubility	≥48.2 mg/mL in DMSO; ≥10.78 mg/mL in H2O with ultrasonic; ≥12.4 mg/mL in EtOH with ultrasonic
Chemical Name	(E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid
SDF	Download SDF
Canonical SMILES	CC(C)C1=NC(=NC(=C1C=CC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C
Shipping Condition	Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips	We do not recommend long-term storage for the solution, please use it up soon.

Cell experiment:[1]
Cell lines	Rat isolated hepatocytes
Reaction Conditions	1.12 nM (IC50)
Applications	Rosuvastatin inhibited the incorporation of sodium [¹⁴C]acetate into cholesterol with an IC50 value of 1.12 nM, and its inhibitory activity on cholesterol biosynthesis was approximately 100 times more potent than pravastatin.
Animal experiment:[1]
Animal models	Normolipemic male beagle dogs
Dosage form	3 mg/kg/day Administered orally for 14 days
Applications	In male beagle dogs with normal cholesterol levels, rosuvastatin (3 mg/kg/day) administration for 14 days decreased plasma cholesterol levels by 26%, higher than 18% in the pravastatin treatment group.
Note	The technical data provided above is for reference only.
	References: 1. Watanabe M, Koike H, Ishiba T, et al. Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors. Bioorganic & Medicinal Chemistry, 1997, 5(2): 437-444.

Purity = 99.07%